Who are ddAC-CP-Olaparib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talazoparib with enzalutamide, Talzenna, NIRAPARIB, Rubraca, Olaparib Treatment D, Pharmacokinetics, Dosage of Niraparib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ddac-cp-olaparib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ddAC-CP-Olaparib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ddAC-CP-Olaparib (ddAC-CP-Olaparib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PARP inhibitor. Area: Oncology.

phase 3 PARP inhibitor PARP Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ddAC-CP-Olaparib (ddAC-CP-Olaparib) — The Netherlands Cancer Institute. ddAC-CP-Olaparib is a PARP inhibitor that works by blocking the enzyme PARP, which is involved in DNA repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ddAC-CP-Olaparib TARGET	ddAC-CP-Olaparib	The Netherlands Cancer Institute	phase 3	PARP inhibitor	PARP
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Talzenna	talazoparib-tosylate	Pfizer	marketed	Poly(ADP-Ribose) Polymerase Inhibitor	PARP1, PARP2	2018-01-01
NIRAPARIB	NIRAPARIB		marketed		PARP-1, PARP-2, CYP17	2017-01-01
Rubraca	RUCAPARIB	Pfizer	marketed		PARP-1, PARP-2, PARP-3	2016-01-01
Olaparib Treatment D	Olaparib Treatment D	AstraZeneca	marketed	PARP inhibitor	PARP1, PARP2
Pharmacokinetics, Dosage of Niraparib	Pharmacokinetics, Dosage of Niraparib	Hospices Civils de Lyon	marketed	PARP inhibitor	PARP1, PARP2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-27 — Talzenna · 8420650 · US
2029-07-27 — Talzenna · 9820985 · US
2029-07-27 — Talzenna · 10780088 · US
2029-10-19 — Talzenna · 8012976 · US
2031-10-20 — Talzenna · 8735392 · US
2031-10-20 — Talzenna · 10189837 · US

Sponsor landscape (PARP inhibitor class)

AstraZeneca · 5 drugs in this class
BeiGene · 2 drugs in this class
Clovis Oncology, Inc. · 1 drug in this class
Fondazione Ricerca Traslazionale · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sanofi · 1 drug in this class
Tesaro, Inc. · 1 drug in this class
The First Affiliated Hospital of Xiamen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ddAC-CP-Olaparib — Competitive Intelligence Brief. https://druglandscape.com/ci/ddac-cp-olaparib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing